LivaNova PLC (NASDAQ:LIVN) Director Hugh M. Morrison sold 1,000 shares of the company’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $115.65, for a total transaction of $115,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ LIVN opened at $122.59 on Thursday. LivaNova PLC has a twelve month low of $76.14 and a twelve month high of $131.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of 37.04, a price-to-earnings-growth ratio of 3.58 and a beta of 0.94.
LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The business had revenue of $272.10 million during the quarter, compared to analyst estimates of $275.03 million. During the same period in the previous year, the company posted $0.83 earnings per share. LivaNova’s revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts forecast that LivaNova PLC will post 3.1 EPS for the current year.
Several equities research analysts recently weighed in on LIVN shares. Stifel Nicolaus upped their price objective on shares of LivaNova from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, September 17th. BidaskClub downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 18th. Jefferies Financial Group upped their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. BTIG Research reissued a “hold” rating on shares of LivaNova in a report on Thursday, November 1st. Finally, Zacks Investment Research downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $119.00.
TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2018/11/08/insider-selling-livanova-plc-livn-director-sells-1000-shares-of-stock-2.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
See Also: Marijuana Stocks
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.